| Literature DB >> 27682100 |
Concetta Gugliandolo1, Antonio Spanò2, Teresa L Maugeri3, Annarita Poli4,5, Adriana Arena6,7, Barbara Nicolaus8,9.
Abstract
Extreme marine environments, such as the submarine shallow vents of the Eolian Islands (Italy), offer an almost unexplored source of microorganisms producing unexploited and promising biomolecules for pharmaceutical applications. Thermophilic and thermotolerant bacilli isolated from Eolian vents are able to produce exopolysaccharides (EPSs) with antiviral and immunomodulatory effects against Herpes simplex virus type 2 (HSV-2). HSV-2 is responsible for the most common and continuously increasing viral infections in humans. Due to the appearance of resistance to the available treatments, new biomolecules exhibiting different mechanisms of action could provide novel agents for treating viral infections. The EPSs hinder the HSV-2 replication in human peripheral blood mononuclear cells (PBMC) but not in WISH (Wistar Institute Susan Hayflic) cells line, indicating that cell-mediated immunity was involved in the antiviral activity. High levels of Th1-type cytokines were detected in PBMC treated with all EPSs, while Th2-type cytokines were not induced. These EPSs are water soluble exopolymers able to stimulate the immune response and thus contribute to the antiviral immune defense, acting as immunomodulators. As stimulants of Th1 cell-mediated immunity, they could lead to the development of novel drugs as alternative in the treatment of herpes virus infections, as well as in immunocompromised host.Entities:
Keywords: Eolian Islands; antivirals; exopolysaccharides; extremophiles; herpes simplex virus; immunomodulators; shallow marine vents
Year: 2015 PMID: 27682100 PMCID: PMC5023242 DOI: 10.3390/microorganisms3030464
Source DB: PubMed Journal: Microorganisms ISSN: 2076-2607
Figure 1Eolian Archipelago (Italy).
Physical and chemical characteristics of thermal fluids emitted from the shallow hydrothermal vents off Eolian Islands (Italy) and related isolates.
| Site | Depth (m) | T (°C) | pH | Conductivity (mS/cm) | Strain |
|---|---|---|---|---|---|
| Bottaro, Panarea Island | 8.0 | 55 | 5.4 | 42.90 | T14 |
| Porto di Levante, Vulcano Island | 0.7 | 70 | 5.2 | - | B3-15, B3-72 |
Differential phenotypic characteristics of the bacilli producing exopolysaccharides, isolated from Eolian shallow vents.
| Phenotypic Characteristics | |||
|---|---|---|---|
| Strain B3-15 | Strain T14 | Strain B3-72 | |
| Growth temperature (°C) | 25–60 | 25–60 | 45–70 |
| Optimum temperature (°C) | 45 | 50 | 65 |
| Growth pH | 5.5–9 | 4–10 | 6–9 |
| Optimum pH | 7 | 8 | 7 |
| Growth NaCl | 0–7 | 2–10 | 0–2 |
| Optimum NaCl | 2 | 5 | 0 |
| Reduction of nitrate to nitrite | − | + | + |
| Catalase | + | + | − |
| Oxidase | + | + | − |
| Starch | − | + | − |
| Tween 20 | + | − | + |
| Tween 80 | + | − | − |
| − | + | − | |
| − | + | − | |
| + | + | − | |
| Inositol | − | + | − |
| + | + | − | |
| − | + | − | |
| Methyl-α- | − | + | − |
| Amygdalin | − | + | − |
| Arbutin | − | + | + |
| Salicin | − | + | + |
| + | + | + | |
| − | + | + | |
| − | + | ||
| − | + | + | |
| + | − | − | |
| − | − | + | |
| Potassium 2-ketogluconate | + | − | + |
| Potassium 5-ketogluconate | + | − | + |
| Bacitracin | + | − | − |
| Polymyxin B | + | + | − |
+: positive; –: negative.
Figure 2Elution profiles from DEAE-Sepharose CL-6B of EPSs fractions produced by Bacillus licheniformis strain B3-15 (a); Geobacillus thermodenitrificans strain B3-72 (b); Bacillus licheniformis strain T14 (c).
Chemical characterization of EPSs produced by bacilli isolated from Eolian shallow vents.
| Properties | EPS2-B3-15 | EPS2-B3-72 | EPS1-T14 |
|---|---|---|---|
| EPS production (mg·L−1) | 165 | 70 | 366 |
| Sugar-media | Glucose | Glucose | Sucrose |
| Carbohydrate content (%) | 66 | 80 | 99 |
| Protein content (%) | 5 | 3 | 1.2 |
| Molecular weight (KDa) | 600 | 400 | 1000 |
| Monosaccharide composition (ratio of relative portion) | Man | Man/Glu (1:0.2) | Fru/Fuc/Glu/GalN/Man (1.0:0.75:0.28:trace:trace) |
| Saccaride repeating unit | Tetrasaccharide | Trisaccharide | Trisaccharide |
| Anomeric configuration | Manno-pyranosidic | Manno-pyranosidic | Manno-pyranosidic |
Figure 3GC-MS of hydrolysed EPSs fractions produced by Bacillus licheniformis strain B3-15 (a); Geobacillus thermodenitrificans strain B3-72 (b); Bacillus licheniformis strain T14 (c).
Figure 41H-NMR and 13C-NMR spectra of EPSs fractions.
Figure 5IR spectrum of the EPS1 produced by B. licheniformis strain T14.
Cytotoxicity percentage on PBMC cells 48-h post-EPSs treatments. Values represent the means of three experiments ±S.D.
| EPS | Cytotoxicity Percentage on PBMC Cells | |||||
|---|---|---|---|---|---|---|
| 200 μg·mL−1 * | 300 μg·mL−1 * | 400 μg·mL−1 * | 500 μg·mL−1 * | 600 μg·mL−1 * | 700 μg·mL−1 * | |
| EPS2-B3-15 | 0 | 0 | 12 ± 2.0 | 29 ± 5.0 | 48 ± 2.9 | 57 ± 4.5 |
| EPS2-B3-72 | 0 | 0 | 4 ± 0.6 | 12 ± 2.2 | 29 ± 6.8 | 40 ± 7.3 |
| EPS1-T14 | 0 | 0 | 0 | 12 ± 1.1 | 31 ± 4.9 | 60 ± 1.9 |
* EPS concentration.
Production of Th-1 cytokines (pg·mL−1) at 48 h post-EPSs treatments by PBMC and under the effect of HSV-2 infection (in grey). Values are expressed as the mean of four experiments ±S.D.
| Inducer | IFN-γ | IFN-α | TNF-α | IL-12 | IL-18 |
|---|---|---|---|---|---|
| None | ˂0.06 | ˂3.1 | ˂0.13 | ˂2.1 | ˂9.2 |
| HSV-2 | ˂0.08 | ˂3.6 | ˂0.12 | ˂2.2 | ˂8.9 |
| EPS2-B3-15 (300 μg·mL−1) | 165 ± 19 *,† | 480 ± 76 *,† | 2151 ± 328 *,† | 420 ± 78 *,† | 140 ± 35 *,† |
| EPS2-B3-72 (300 μg·mL−1) | 115 ± 18 *,† | 116 ± 13 *,† | 1980 ± 101 *,† | 320 ± 49 *,† | 183 ± 29 *,† |
| EPS1-T14 (300 μg·mL−1) | 58 ± 13 *,† | 45 ± 3 *,† | 610 ± 43 *,† | 128 ± 19 *,† | 49 ± 3 *,† |
| EPS1-T14 (400 μg·mL−1) | 105 ± 28 *,† | 108 ± 25 *,† | 1310 ± 73 *,† | 358 ± 69 *,† | 86 ± 3 *,† |
| EPS2-B3-15 (300 μg·mL−1) + HSV-2 | 79 ± 24 | 295 ± 93 | 780 ± 98 | 115 ± 28 | 84 ± 22 |
| EPS2-B3-72 (300 μg·mL−1) + HSV-2 | 61 ± 9 | 42 ± 5 | 680 ± 71 | 122 ± 17 | 95 ± 13 |
| EPS1-T14 (300 μg·mL−1) + HSV-2 | 27 ± 2 | 29 ± 2 | 301 ± 28 | 57 ± 11 | 23 ± 8 |
| EPS1-T14 (400 μg·mL−1) + HSV-2 | 37 ± 2 | 26 ± 2 | 317 ± 88 | 166 ± 20 | 28 ± 10 |
* Significantly different (P ˂ 0.05) compared with untreated control; † Significantly different (P ˂ 0.05) compared with exopolymer treated PBMC and HSV-2 infected.
Production of Th2 cytokines (IL-4 and IL-10) (pg·mL−1) at 48 h post-EPSs treatments by PBMC and under the effect of HSV-2 infection (in grey). Values are expressed as mean of four experiments ±S.D.
| Inducer | IL-4 | IL-10 |
|---|---|---|
| None | ˂0.1 | ˂0.5 |
| HSV-2 | 41 ± 6 | 35 ± 5 |
| EPS2-B3-15 (300 μg·mL−1) | ˂0.1 | ˂0.5 |
| EPS2-B3-72 (300 μg·mL−1) | ˂0.1 | ˂0.5 |
| EPS1-T14 (400 μg·mL−1) | ˂0.1 | ˂0.5 |
| EPS2-B3-15 (300 μg·mL−1) + HSV-2 | ˂0.1 * | ˂0.5 * |
| EPS2-B3-72 (300 μg·mL−1) + HSV-2 | ˂0.1 * | ˂0.5 * |
| EPS1-T14 (400 μg·mL−1) + HSV-2 | 23 ± 6 | 37 ± 2 |
* Significantly different (P ˂ 0.05) compared with PBMC infected with HSV-2.